The most advanced human clinical trial on lion's mane and Alzheimer's disease — a 49-week double-blind placebo-controlled study of 49 patients with mild Alzheimer's disease — found significantly less cognitive deterioration in the treatment group compared to placebo, alongside measurably higher plasma Nerve Growth Factor levels. Preclinical research consistently demonstrates reductions in amyloid-beta plaques, phosphorylated tau, and improvements in spatial memory and learnin

Two randomized controlled trials have found that Hericium erinaceus supplementation significantly reduces anxiety and depression scores compared to placebo. The proposed mechanism is biological rather than behavioral: lion's mane supports the neurotrophin signaling pathways — NGF and BDNF — that antidepressant medications target pharmacologically, while simultaneously reducing neuroinflammation, a process now recognized as a core driver of mood disorders. The clinical evidenc

Nerve Growth Factor (NGF) is a protein the brain requires to maintain and repair neurons throughout life. Its levels decline with age, and that decline is causally implicated in Alzheimer's disease, Parkinson's disease, and age-related memory loss. Lion's mane is the only widely consumed food known to contain compounds that directly stimulate NGF synthesis inside the central nervous system. The mechanism has been characterized to the molecular level: two classes of terpenoids

Four randomized controlled trials — including studies in older adults with mild cognitive impairment and double-blind trials in healthy younger populations — have found measurable improvements in memory and cognitive performance associated with Hericium erinaceus supplementation. The mechanism is well characterized: hericenones and erinacines stimulate Nerve Growth Factor synthesis, supporting neuronal survival and synaptic plasticity. Effects have been observed both acutely

Lion's mane (Hericium erinaceus) is the only edible mushroom known to contain hericenones and erinacines — terpenoid compounds with demonstrated ability to cross the blood-brain barrier and stimulate the synthesis of Nerve Growth Factor, a protein critical to the survival, maintenance, and repair of neurons. Clinical trials have documented improvements in cognitive function, reductions in anxiety and depression, and measurable effects on neurodegeneration. A 2025 systematic r